<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   IgA nephropathy: Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       IgA nephropathy: Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        IgA nephropathy: Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Chee Kay Cheung, PhD, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Barratt, PhD, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Fernando C Fervenza, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosanna Coppo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 05, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H303282162">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgA nephropathy (IgAN) is the most common cause of primary (idiopathic) glomerulonephritis in resource-abundant settings.
        </p>
        <p>
         The epidemiology, pathology, clinical features, and diagnosis of IgAN will be reviewed here. Other aspects of IgAN are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3095.html" rel="external">
          "IgA nephropathy: Pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7344.html" rel="external">
          "IgA nephropathy: Recurrence after transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1230197142">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgAN is the most common lesion found to cause primary glomerulonephritis throughout most resource-abundant countries of the world [
         <a href="#rid1">
          1
         </a>
         ]. IgAN occurs with greatest frequency in East Asian individuals and White individuals and is relatively rare in Black individuals [
         <a href="#rid2">
          2-4
         </a>
         ]. In a Chinese study of 13,519 kidney biopsies, for example, IgAN constituted 45 percent of all cases of primary glomerulonephritis [
         <a href="#rid3">
          3
         </a>
         ]. An international kidney biopsy survey found that IgAN accounted for 22 and 11 percent of glomerular disease diagnoses in Europe and North America, respectively [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Variations in disease prevalence may reflect regional differences in screening for kidney disease and kidney biopsy practices [
         <a href="#rid3">
          3,6
         </a>
         ]. IgAN can only be diagnosed upon evaluation of a kidney biopsy with immunofluorescence microscopy. Thus, the incidence and prevalence of IgAN will be higher in places where kidney biopsies are performed more frequently. Many patients with IgAN are detected on routine urine screening because their only clinical manifestation is asymptomatic hematuria and/or proteinuria. Prevalence may therefore appear to be higher in countries with an active urine testing program and a low threshold for the performance of kidney biopsy in patients with isolated asymptomatic hematuria, such as Japan and Korea, where testing is routinely performed in schools and in the workplace. Conversely, clinicians in North America seldom biopsy a patient with isolated hematuria or mild proteinuria, resulting in an apparently lower disease prevalence. In some resource-limited countries, the lack of routine immunofluorescence microscopy precludes an exact evaluation of disease prevalence.
        </p>
        <p>
         Patients with IgAN may present at any age, but there is a peak incidence in the second and third decades of life. There is approximately a 2:1 male-to-female predominance in North American and Western European populations in both adults and children, although the sexes are equally affected among populations in East Asia [
         <a href="#rid7">
          7,8
         </a>
         ]. Significant heterogeneity in clinical presentation and pathological features also exists between geographical locations, which may in part explain differences in response to immunomodulatory therapies [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2981497375">
         <span class="h1">
          PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H1332645434">
         <span class="h2">
          Histologic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathognomic finding for IgAN is the presence of mesangial deposits of IgA, which are demonstrated by immunofluorescence microscopy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunofluorescence microscopy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          IgA
         </strong>
         – Immunofluorescence microscopy demonstrates dominant or codominant mesangial deposits of IgA, either alone, with IgG, with IgM, or with both IgG and IgM  (
         <a class="graphic graphic_picture graphicRef69895" href="/z/d/graphic/69895.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef58102" href="/z/d/graphic/58102.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Deposited IgA is predominantly J chain-containing polymeric IgA1, with a predominance for lambda light chains. Subendothelial capillary wall IgA deposits may also be present in up to one-third of patients, and this is associated with higher histologic activity (increased mesangial and endocapillary hypercellularity) and worse kidney outcome [
         <a href="#rid9">
          9
         </a>
         ]. IgG codeposition is observed in approximately one-third of cases and has been reported to be an independent risk factor for poor kidney outcome [
         <a href="#rid10">
          10
         </a>
         ]. Mesangial deposition of secretory IgA has also been observed, although the pathogenic significance of this is unknown [
         <a href="#rid9">
          9-11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The immunofluorescence findings in IgAN are indistinguishable from those in IgA vasculitis (Henoch-Schönlein purpura) nephritis. (See
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complement
         </strong>
         – Glomerular deposition of complement component C3 is found in over 90 percent of cases [
         <a href="#rid12">
          12
         </a>
         ]. C1q is almost always absent, implying that complement is activated via the alternative and/or lectin pathways. Deposits of components of the alternative pathway, properdin and Factor H, may often be found [
         <a href="#rid12">
          12
         </a>
         ]. Glomerular deposition of complement factor H-related protein 5 (CFHR5), a positive regulator of the alternative pathway, was observed more frequently in patients with progressive IgAN compared with those who have nonprogressive disease [
         <a href="#rid13">
          13
         </a>
         ]. The presence of mesangial C4d deposits, signifying lectin pathway activation in the absence of C1q, has been identified as a risk factor for worse long-term kidney outcomes in IgAN [
         <a href="#rid13">
          13-16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other
         </strong>
         – Glomerular fibrin deposition may be observed in the mesangium or along the endothelial surface, although this is more commonly seen in IgA vasculitis (Henoch-Schönlein purpura) nephritis. (See
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Light microscopy
         </strong>
         – While mesangial IgA deposition is diffuse and global in IgAN, there is significant heterogeneity in the pathologic response to this deposition, which may be focal (involving less than 50 percent of glomeruli) and segmental. The major finding on light microscopy, mesangial hypercellularity and matrix expansion, is commonly focal  (
         <a class="graphic graphic_picture graphicRef62380" href="/z/d/graphic/62380.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. In patients with IgAN and rapidly deteriorating kidney function, segmental necrosis with or without crescent formation is often seen, a finding consistent with an ongoing "capillaritis."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A later diagnosis with decreased glomerular filtration rate (GFR) and increased proteinuria is commonly associated with a kidney biopsy displaying features of chronic disease: glomerulosclerosis, tubulointerstitial inflammation, tubular atrophy, and interstitial fibrosis [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thrombotic microangiopathy (TMA) has been variably described in association with IgAN. It is often associated with uncontrolled or malignant hypertension and portends a poor kidney outcome [
         <a href="#rid19">
          19-22
         </a>
         ]. This lesion was not commonly observed in the Oxford classification study and subsequent validation studies and, therefore, may be subject to variability in its interpretation [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Oxford classification of IgAN'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electron microscopy
         </strong>
         – Electron microscopy typically reveals electron-dense deposits that are primarily limited to the mesangium (which are outside of mesangial cells in the mesangial spaces) but may also occur in the subendothelial and subepithelial spaces. The number and size of these deposits generally correlates well with the severity of changes seen on light microscopy [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some patients with IgAN have coexisting diffuse thinning of the glomerular basement membrane that is indistinguishable from thin basement membrane nephropathy [
         <a href="#rid24">
          24,25
         </a>
         ]. Exome sequence analysis of patients with IgAN and thin basement membrane disease has identified diagnostic variants of the
         <em>
          COL4A3
         </em>
         /
         <em>
          COL4A4
         </em>
         /
         <em>
          COL4A5
         </em>
         genes in one-third of cases [
         <a href="#rid26">
          26
         </a>
         ]. It is not clear whether the clinical course of such patients differs from typical IgAN [
         <a href="#rid24">
          24,25
         </a>
         ]. Observational data from France suggests that such patients may have a more benign outcome, due possibly to lead-time bias, as hematuria brings them to the attention of clinicians at an earlier time in the natural history of disease [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3038.html" rel="external">
          "Thin basement membrane nephropathy (benign familial hematuria)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is some evidence that a subset of IgAN cases with clinical features resembling those of minimal change disease display biopsy features typical of a podocytopathy. Whether this represents a discrete subclass of IgAN remains to be clarified [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4151386471">
         <span class="h2">
          Oxford classification of IgAN
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2009, a pathologic classification of IgAN was developed by the International IgA Nephropathy Network in collaboration with the Renal Pathology Society, based upon clinical data and kidney biopsies from 265 White patients and East Asian patients followed for a median of five years [
         <a href="#rid29">
          29,30
         </a>
         ]. This pathologic scoring system, known as the Oxford classification, scores kidney biopsies based upon histologic variables that have been shown to independently predict kidney outcome in patients with IgAN. The Oxford classification schema has subsequently been validated in several cohorts and refined for clinical use in both adults and children with IgAN [
         <a href="#rid31">
          31-35
         </a>
         ].
        </p>
        <p>
         Based upon this work, the consensus recommendation is that every biopsy report of IgAN should include numerical scores based upon the presence or absence of the following five variables (MEST-C) [
         <a href="#rid36">
          36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          M
         </strong>
         esangial hypercellularity – Mesangial cells are counted per mesangial area, and a score of zero to three is assigned for each glomerulus. A score of zero indicates that fewer than four mesangial cells are present per mesangial area; a score of one indicates that four to five mesangial cells are present per mesangial area; a score of two indicates that six to seven mesangial cells are present per mesangial area; a score of three indicates that greater than eight mesangial cells are present per mesangial area. Scores obtained for all glomeruli are averaged, and the resulting assigned hypercellularity score is either M0 if the mean score is less than 0.5 or M1 if the mean score is greater than 0.5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          E
         </strong>
         ndocapillary hypercellularity – This is defined as present (E1) if hypercellularity is present within glomerular capillary lumens and results in narrowing of the lumens, or absent (E0) if no hypercellularity is present within lumens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          S
         </strong>
         egmental glomerulosclerosis – This is defined as present (S1) if any part of the glomerular tuft is involved in sclerosis, or absent (S0) if no segmental glomerulosclerosis is present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T
         </strong>
         ubular atrophy/interstitial fibrosis – The percentage of the cortical area involved by tubular atrophy or interstitial fibrosis is quantitated. A score of T0, T1, or T2 is given if the percentage of involved cortical area is 0 to 25, 26 to 50, or &gt;50 percent, respectively. Note that scoring of tubular atrophy/interstitial fibrosis was preferred to global glomerulosclerosis, as its quantification is less susceptible to error due to subcapsular sampling or paucity of glomeruli on the biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          C
         </strong>
         rescents – This feature is defined as present if cellular and/or fibrocellular crescents are present in at least one glomerulus (C1), present in at least 25 percent of glomeruli (C2), or absent (C0). Fibrous crescents are not counted toward this score.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biopsies with fewer than eight glomeruli should be considered of uncertain value for prognosis.
        </p>
        <p>
        </p>
        <p>
         A number of pathological features occasionally found in IgAN were not included on the Oxford classification, such as interstitial inflammation, TMA, and fibrinoid necrosis. This may be due to lack of interobserver reliability or that these lesions were not commonly observed, which may in part be due to patient selection (patients with rapidly progressive disease were excluded from the original cohort).
        </p>
        <p>
         A prediction tool, which combines clinical and histologic (MEST-C) data at diagnosis, has been developed and externally validated and predicts the risk of worsening kidney function (defined by a 50 percent decline in eGFR or development of ESKD) within five years from kidney biopsy [
         <a href="#rid37">
          37
         </a>
         ]. Use of this prediction tool is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'Assessment of risk'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2588332002">
         <span class="h2">
          IgA deposits in healthy individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgA deposits may be seen on kidney biopsies of individuals with no evidence of kidney disease [
         <a href="#rid38">
          38
         </a>
         ]. The reported incidence of mesangial IgA deposition in apparently healthy individuals ranges from 3 to 16 percent [
         <a href="#rid38">
          38-40
         </a>
         ]. These cases had no clinical features of nephritis, but their kidney biopsy was consistent with IgAN.
        </p>
        <p>
         This observation raises three important points:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is a large cohort of undiagnosed "latent" IgAN in the general population, most pronounced in East Asian populations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         This finding must be considered when genetic studies are undertaken comparing gene polymorphisms in IgAN with "healthy" populations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It raises an important consideration for the pathogenesis of IgAN: The process of mesangial IgA deposition may be separate from the induction of glomerular injury, and IgA deposition does not necessarily need to be followed by nephritis. Identifying the independent factors that may be critical to each of these processes may improve our overall understanding of the pathogenesis of IgAN. (See
         <a class="medical medical_review" href="/z/d/html/3095.html" rel="external">
          "IgA nephropathy: Pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Interestingly, there have been cases reported of patients who have inadvertently received a kidney transplant containing IgA deposits. These deposits have been shown to resolve on subsequent biopsy of the graft, indicating that the disease process in IgAN is systemic rather than being confined to the kidney [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3160025400">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H1891688247">
         <span class="h2">
          Clinical presentations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with IgAN may present with a range of clinical presentations, from asymptomatic microscopic hematuria to rapidly progressive glomerulonephritis. The relative frequency of these presentations depends in part upon screening practices (which will lead to increased discovery of asymptomatic cases) and the particular population being evaluated [
         <a href="#rid2">
          2,6
         </a>
         ]. As an example, some studies have shown that patients of South or East Asian ancestry with IgAN, compared with those of other origin, may present with more severe clinical features and have a higher risk of progression to ESKD [
         <a href="#rid42">
          42-44
         </a>
         ].
        </p>
        <p>
         Clinical presentations among patients with IgAN including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gross hematuria
         </strong>
         – Approximately 40 to 50 percent present with one or recurrent episodes of gross (visible) hematuria, often accompanying an upper respiratory infection. This has sometimes been called "synpharyngitic hematuria." These episodes can be provoked by bacterial tonsillitis or by viral upper respiratory infections; they may also occur rarely in individuals who have already undergone tonsillectomy. It is frequently presumed, although not proven, that the first episode represents the onset of the disease. Patients may complain of flank pain during acute episodes, which usually reflects stretching of the kidney capsules. Low-grade fever may also be present. These features can mimic urinary tract infection or urolithiasis. Most patients have only a few episodes of gross hematuria, and episodes usually recur for a few years at most. An initial episode of gross hematuria at age 40 years or older is rarely due to IgAN, and other diagnoses must be assessed. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microscopic hematuria with or without proteinuria
         </strong>
         – Another 30 to 40 percent have microscopic hematuria and usually mild proteinuria and are incidentally detected on a routine examination or during a diagnostic evaluation for chronic kidney disease [
         <a href="#rid45">
          45,46
         </a>
         ]. In these patients, the disease is of uncertain duration. On urine microscopy, dysmorphic red blood cells, and in particular urinary acanthocytes, are regarded as being an indicator of glomerular pathology [
         <a href="#rid47">
          47
         </a>
         ]. Gross hematuria will eventually occur in 20 to 25 percent of these patients. (See
         <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">
          "Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Isolated glomerular hematuria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nephrotic syndrome or rapidly progressive glomerulonephritis
         </strong>
         – Less than 10 percent present with either nephrotic syndrome or an acute, rapidly progressive glomerulonephritis characterized by edema, hypertension, and kidney function impairment as well as hematuria. Rarely, IgAN may present with malignant hypertension. It is usually presumed that patients have longstanding disease that was not detected earlier because the patient did not have gross hematuria or undergo routine urinalysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute kidney injury
         </strong>
         – Rarely, patients develop acute kidney injury with or without oliguria. This may be due to crescentic IgAN or to heavy glomerular hematuria leading to tubular occlusion and/or damage by red cells. The latter is usually a reversible phenomenon, although incomplete recovery of kidney function may occur [
         <a href="#rid48">
          48
         </a>
         ]. If there is crescentic IgAN, there will be an increase in the absolute number of dysmorphic red cells excreted in the urine that is typically at least 50 percent of all red cells seen.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1870879420">
         <span class="h2">
          Differences between children and adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children with IgAN, gross hematuria is more common than in adults, which may lead to earlier diagnosis [
         <a href="#rid8">
          8,49
         </a>
         ]. Inflammatory lesions and mesangial and/or endocapillary hypercellularity are also more prevalent on kidney biopsy in children with IgAN compared with adults [
         <a href="#rid31">
          31
         </a>
         ]. In contrast with adults, who usually have a linear rate of estimated glomerular filtration rate (eGFR) decline, children experience an initial increase in eGFR, which may last up to several years, followed by a linear decline similar to that seen in adults [
         <a href="#rid50">
          50
         </a>
         ]. Postulated causes for this include the more frequent episodes of acute nephritic syndrome and hematuria and higher rates of clinical remission in children compared with adults.
        </p>
        <p class="headingAnchor" id="H1865092422">
         <span class="h2">
          Associated conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgAN may be associated with other conditions [
         <a href="#rid51">
          51
         </a>
         ]. Some associations are well established, others are anecdotal observations that should be interpreted with caution because IgAN is a common disease, and any association may be coincidental rather than causal. As previously mentioned, the reported incidence of mesangial IgA deposition in apparently healthy individuals ranges from 3 to 16 percent [
         <a href="#rid38">
          38,39
         </a>
         ]. Thus, the likelihood of finding mesangial IgA deposits by chance in association with other common diseases is relatively high. (See
         <a class="local">
          'IgA deposits in healthy individuals'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic liver disease
         </strong>
         – Mesangial IgA deposition associated with chronic liver disease, particularly alcoholic cirrhosis, is the most common form of secondary IgAN [
         <a href="#rid52">
          52,53
         </a>
         ]. It can also occur in chronic liver disease due to other causes, including hepatitis B and C [
         <a href="#rid54">
          54,55
         </a>
         ] and, in children, end-stage liver disease due mostly to alpha-1 antitrypsin deficiency or biliary atresia [
         <a href="#rid56">
          56
         </a>
         ]. Despite the frequency of glomerular IgA deposits in advanced liver disease, most adults have no clinical signs of glomerular disease [
         <a href="#rid52">
          52-54
         </a>
         ], while up to one-third of children may have asymptomatic microscopic hematuria or proteinuria [
         <a href="#rid56">
          56
         </a>
         ]. The urinary abnormalities that may be seen in children typically resolve after successful liver transplantation [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Impaired removal of IgA-containing complexes by the Kupffer cells in the liver is thought to predispose to IgA deposition in the kidney [
         <a href="#rid57">
          57
         </a>
         ]. The observation that IgA may also be deposited in the skin and hepatic sinusoids is compatible with this hypothesis [
         <a href="#rid58">
          58
         </a>
         ]. As in primary IgAN, polymeric IgA1 appears to be the dominant IgA isoform deposited, although there is some evidence for codeposition of IgA2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Celiac disease
         </strong>
         – Glomerular IgA deposition is common in celiac disease, occurring in as many as one-third of patients. As in liver disease, the great majority of affected patients have no clinical manifestations of kidney disease, perhaps because there is no associated activation of complement [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ingestion of gliadin in this disorder leads to the formation of IgA antigliadin antibodies, with the subsequent deposition of gliadin-antigliadin immune complexes in the glomeruli [
         <a href="#rid60">
          60
         </a>
         ]. This can occur in patients both with overt celiac disease and those with no symptoms but mucosal atrophy on intestinal biopsy. The level of circulating IgA complexes appears to correlate with disease activity in the occasional patient with clinically evident IgAN. However, gliadin deposition cannot be demonstrated in the glomeruli, suggesting that gluten might act by increasing intestinal permeability and enhancing the absorption of other dietary antigens [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Institution of a gluten-free diet in patients with circulating antigliadin antibodies results, in most cases, in a temporary but nonsustained reduction in microscopic hematuria and proteinuria and has no impact on long-term kidney survival [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – Although the collapsing variant of focal segmental glomerulosclerosis (FSGS) is the classic glomerulopathy seen with HIV infection, other glomerular diseases have also been associated with HIV infection, including IgAN [
         <a href="#rid63">
          63-65
         </a>
         ]. Patients with IgAN present with gross or microscopic hematuria and asymptomatic proteinuria compared with the nephrotic syndrome in FSGS. (See
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The polyclonal increase in serum IgA, seen in HIV infection, has been cited as a predisposing factor. In at least some cases of HIV-associated IgAN, idiotypic IgA antibodies reactive with anti-HIV IgG or IgM antibodies can be demonstrated both in the systemic circulation and in the kidney [
         <a href="#rid65">
          65
         </a>
         ]. Furthermore, the HIV genome can be detected in the kidney, suggesting a possible initiating role of viral infection in the glomerular cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prevalence of IgA deposits in patients infected with HIV is uncertain. One report of 116 postmortem examinations found mesangial IgA deposits in 8 percent of patients [
         <a href="#rid63">
          63
         </a>
         ]. However, most affected patients had little or no mesangial hypercellularity, and urinary abnormalities were mild in all cases. Thus, subclinical disease or incidental IgA deposition appears to be much more common than overt IgAN, similar to the findings noted above in cirrhosis and celiac disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monoclonal gammopathy of renal significance (MGRS)
         </strong>
         – These are a group of disorders in which a monoclonal protein causes kidney damage but without evidence of overt hematological malignancy (see
         <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">
          "Diagnosis and treatment of monoclonal gammopathy of renal significance"
         </a>
         ). In MGRS, deposition of monoclonal IgA occurs less frequently compared with IgG. Two subtypes of glomerulopathies have been described: alpha-heavy chain deposition disease and IgA-proliferative glomerulonephritis with monoclonal immunoglobulin deposits (IgA-PGNMID), which shares common clinical and pathological features with IgG-PGNMID [
         <a href="#rid66">
          66
         </a>
         ]. Distinction between these conditions and IgAN, where polyclonal IgA is deposited, is important as IgA-associated MGRS may respond to clone-directed therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glomerular diseases
         </strong>
         – IgAN may occur in association with other glomerular disorders:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Minimal change disease
         </strong>
         – Some patients with IgAN have an acute onset of the nephrotic syndrome in which there is only mild mesangial proliferation on kidney biopsy and the most prominent finding is diffuse foot process effacement, similar to that seen in minimal change disease [
         <a href="#rid67">
          67-70
         </a>
         ]. This presentation is more frequent in children [
         <a href="#rid71">
          71
         </a>
         ]. Many of these patients behave as if they have minimal change disease, with remission of proteinuria being induced by glucocorticoid therapy. The mechanism underlying this association is not understood, and the IgA deposits may represent a chance occurrence [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">
          "IgA nephropathy: Treatment and prognosis", section on 'IgA nephropathy with apparent minimal change disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Granulomatosis with polyangiitis
         </strong>
         – IgAN has been described in patients with granulomatosis with polyangiitis who were in clinical remission after initial immunosuppressive therapy [
         <a href="#rid72">
          72
         </a>
         ]. These patients had repeated upper respiratory infections (perhaps due in part to the immunosuppression) and presented with new hematuria, but no apparent recurrence of systemic vasculitis or new elevation in anti-neutrophil cytoplasmic antibodies titers. The latter findings suggest the possibility of a new kidney disease rather than relapsing vasculitis. (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are also a number of reports documenting IgA deposition in patients with thin basement membrane nephropathy, lupus nephritis, diabetic nephropathy, membranous nephropathy, and IgA-dominant
         <em>
          Staphylococcus
         </em>
         -associated postinfectious glomerulonephritis. With the exception of IgA-dominant postinfectious
         <em>
          Staphylococcus
         </em>
         -associated glomerulonephritis, these findings are most probably due to chance associations because IgA deposition is common in the general population. (See
         <a class="medical medical_review" href="/z/d/html/86317.html" rel="external">
          "Staphylococcus-associated glomerulonephritis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other conditions
         </strong>
         – IgAN has been infrequently associated with a variety of other diseases including dermatitis herpetiformis, seronegative arthritis (particularly ankylosing spondylitis), small cell carcinoma, lymphoma (Hodgkin lymphoma and T-cell lymphomas, including mycosis fungoides), disseminated tuberculosis, bronchiolitis obliterans, and inflammatory bowel disease (Crohn disease and ulcerative colitis) [
         <a href="#rid73">
          73-84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H455226641">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H393170550">
         <span class="h2">
          When to suspect IgAN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the range of clinical presentations among patients with IgAN (see
         <a class="local">
          'Clinical presentations'
         </a>
         above), the diagnosis of IgAN should be suspected in any patient who presents with one or more of the following clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One or more episodes of gross hematuria, especially if accompanied by an upper respiratory infection
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent microscopic hematuria with or without proteinuria
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Slowly progressive kidney function impairment
        </p>
        <p>
        </p>
        <p>
         As discussed previously, patients with IgAN may present less commonly with nephrotic syndrome or rapidly progressive glomerulonephritis.
        </p>
        <p class="headingAnchor" id="H2674984985">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of IgAN is confirmed by kidney biopsy, with immunofluorescence or immunoperoxidase staining demonstrating the presence of dominant or codominant deposition of IgA. There are no specific laboratory findings that can be used to reliably diagnose IgAN. After a diagnosis of IgAN has been established, underlying causes of secondary IgAN (eg, liver cirrhosis) should be considered according to the patient's coexisting medical conditions. (See
         <a class="local">
          'Histologic features'
         </a>
         above and
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
         However, a kidney biopsy may not be indicated in every patient suspected of having IgAN, depending upon their clinical presentation. As an example, a kidney biopsy is not usually performed for patients presenting with isolated hematuria (ie, without evidence of proteinuria or impaired kidney function), since establishing the diagnosis frequently does not alter the course of treatment in such patients. In such patients, a kidney biopsy is usually performed only if there are signs suggestive of more severe or progressive disease, such as persistent proteinuria of at least 500 mg per day or an elevated serum creatinine concentration. Indications for performing a kidney biopsy vary geographically, and in some countries, there is a greater willingness of nephrologists to biopsy patients who have persistent microscopic hematuria with preserved kidney function and without proteinuria. (See
         <a class="medical medical_review" href="/z/d/html/3067.html" rel="external">
          "The kidney biopsy", section on 'Appropriate use of kidney biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults", section on 'Role of kidney biopsy'
         </a>
         .)
        </p>
        <p>
         This geographic variability in kidney biopsy indications may, at least in part, explain why IgAN is diagnosed at earlier stages of disease in some countries and at later stages in others. In a study from Japan, for example, where mandatory kidney screening programs have been implemented since the 1970s, approximately 30 percent of patients with biopsy-proven primary IgAN had chronic kidney disease (CKD) stage 3 or higher, and approximately 5 percent had CKD stage 4 or 5 at the time of diagnosis [
         <a href="#rid85">
          85
         </a>
         ]. By contrast, in a study from the United States (which does not have mandatory kidney screening programs), 75 percent of patients had CKD stage 3 or higher, and 42 percent had CKD stage 4 or 5 at the time of diagnosis [
         <a href="#rid86">
          86
         </a>
         ]. Higher CKD stages were associated with an increased odds of higher Oxford classification (MEST-C) scores (more extensive histological injury). Thus, deferring a kidney biopsy until the patient has evidence of more severe disease may result in patients being diagnosed at later stages in the disease course. (See
         <a class="local">
          'Oxford classification of IgAN'
         </a>
         above.)
        </p>
        <p>
         A number of other tests have been proposed for the evaluation and diagnosis of IgAN, including measurement of poorly galactosylated IgA1 O-glycoforms and/or poorly galactosylated IgA1-specific IgG antibodies in the serum [
         <a href="#rid87">
          87,88
         </a>
         ], and measurement of certain microRNAs (miRNAs) that affect O-galactosylation of IgA1 [
         <a href="#rid89">
          89,90
         </a>
         ], among others. However, none of these tests have clearly been shown to have utility as diagnostic biomarkers for IgAN.
        </p>
        <p class="headingAnchor" id="H4118700164">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who are suspected of having IgAN, the differential diagnosis includes the following conditions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alport syndrome (also referred to as hereditary nephritis) and thin basement membrane nephropathy are the two other major glomerulopathies that present with persistent isolated hematuria [
         <a href="#rid91">
          91,92
         </a>
         ]. The diagnosis of any of these disorders can only be made by kidney biopsy, or by inference in Alport syndrome if there is a family history of kidney failure with or without deafness, or in thin basement membrane disease if approximately one-half of first-degree relatives have hematuria. (See
         <a class="medical medical_review" href="/z/d/html/3053.html" rel="external">
          "Isolated and persistent glomerular hematuria in adults", section on 'Causes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poststreptococcal glomerulonephritis (PSGN) may also present with gross hematuria after an upper respiratory tract infection. However, the time interval between the antecedent illness and the development of hematuria is usually longer in PSGN (more than 10 versus less than 5 days in IgAN). In addition, patients with IgAN may have repeated episodes of gross hematuria, which are rare in PSGN. (See
         <a class="medical medical_review" href="/z/d/html/6118.html" rel="external">
          "Poststreptococcal glomerulonephritis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune complex/monoclonal immunoglobulin- or complement-mediated membranoproliferative glomerulonephritis may also present with episodic gross hematuria in children and young adults and should therefore be considered in the differential diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/3055.html" rel="external">
          "Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgA-dominant Staphylococcus-associated glomerulonephritis typically presents with acute kidney injury, hematuria, and proteinuria. Older adult patients and those with diabetes mellitus are most commonly affected. The majority of reported cases are associated with
         <em>
          Staphylococcus aureus
         </em>
         infection [
         <a href="#rid93">
          93
         </a>
         ]. In contrast with poststreptococcal glomerulonephritis, in which glomerular deposition of IgG and/or C3 is predominant, IgA-dominant Staphylococcus-associated glomerulonephritis is characterized by IgA deposition [
         <a href="#rid94">
          94
         </a>
         ]. Diffuse proliferative glomerulonephritis with infiltration of neutrophils and subepithelial and subendothelial electron-dense deposits are more prevalent in Staphylococcus-associated glomerulonephritis. (See
         <a class="medical medical_review" href="/z/d/html/86317.html" rel="external">
          "Staphylococcus-associated glomerulonephritis in adults", section on 'Distinction from IgA nephropathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgA vasculitis (Henoch-Schönlein purpura) has kidney findings that are histologically identical to that in IgAN. However, patients with IgA vasculitis typically have other extrarenal manifestations, such as rash, arthralgias, and abdominal pain. (See
         <a class="medical medical_review" href="/z/d/html/3107.html" rel="external">
          "IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lupus nephritis is another disorder associated with prominent mesangial IgA deposition. Lupus nephritis can be distinguished from IgAN histologically by the more prominent deposition of IgG than IgA and the presence of substantial C1q deposition, indicating activation of the classical complement pathway, as opposed to activation of the alternative and/or lectin pathway in IgA nephropathy [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">
          "Lupus nephritis: Diagnosis and classification"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other differential diagnoses include Fabry disease (which has been reported to occur coincidentally with IgAN [
         <a href="#rid95">
          95
         </a>
         ]), non-IgA mesangial proliferative glomerulonephritis, and MGRS including IgA-PGNMID. (See
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3661183200">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">
          "Society guideline links: Glomerular disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H452421034">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83746.html" rel="external">
          "Patient education: IgA nephropathy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2133510204">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – IgA nephropathy (IgAN) is the most common lesion found to cause primary glomerulonephritis throughout most resource-abundant countries of the world. Patients with IgAN may present at any age, but there is a peak incidence in the second and third decades of life. There is a 2:1 male-to-female predominance in North American and Western European populations in both adults and children, although the sexes are equally affected among populations in East Asia. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – IgAN is characterized pathologically by prominent, globular deposits of IgA in the mesangium on immunofluorescence microscopy. Light microscopy shows diffuse mesangial proliferation and matrix expansion with proliferative glomerulonephritis and segmental glomerulosclerosis and tubulointerstitial fibrosis and inflammation in more advanced disease. Electron microscopy shows dense deposits primarily in the mesangium  (
         <a class="graphic graphic_picture graphicRef69895" href="/z/d/graphic/69895.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef62380" href="/z/d/graphic/62380.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef58102" href="/z/d/graphic/58102.html" rel="external">
          picture 2
         </a>
         ). The Oxford classification of IgAN identifies variables that are correlated with kidney outcomes independent of the clinical features at baseline, the proteinuria level, and blood pressure control. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Most patients with IgAN present with either gross hematuria (single or recurrent), usually accompanying an upper respiratory infection, or microscopic hematuria with or without mild proteinuria incidentally detected on a routine examination. These symptoms are often accompanied by hypertension. Less commonly, patients may present with either nephrotic syndrome or an acute, rapidly progressive glomerulonephritis. Patients may rarely develop acute kidney injury with or without oliguria, due to crescentic IgAN or to gross hematuria causing tubular occlusion and/or damage by red cells. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Associated conditions
         </strong>
         – IgAN may be associated with other conditions. Mesangial IgA deposition, which is often clinically silent, may also be seen with chronic liver disease, celiac disease, HIV infection, and monoclonal gammopathy of renal significance (MGRS). In addition, IgAN may rarely be seen with other glomerular diseases, including minimal change disease, membranous nephropathy, and granulomatosis with polyangiitis. (See
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of IgAN should be suspected in any patient who presents with one or more episodes of gross hematuria (especially if accompanied by an upper respiratory infection), persistent microscopic hematuria with or without proteinuria, or slowly progressive kidney function impairment. The diagnosis is confirmed by kidney biopsy. However, a kidney biopsy is usually performed only if there are signs suggestive of more severe or progressive disease, such as persistent proteinuria of at least 500 mg per day or an elevated serum creatinine concentration. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2721472326">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledges John Feehally, DM, FRCP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galla JH. IgA nephropathy. Kidney Int 1995; 47:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 2004; 66:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowley-Nowick PA, Julian BA, Wyatt RJ, et al. IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course. Kidney Int 1991; 39:1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Shaughnessy MM, Hogan SL, Thompson BD, et al. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transplant 2018; 33:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo SC, Goh SM, Barratt J. Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology (Carlton) 2019; 24:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selewski DT, Ambruzs JM, Appel GB, et al. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney Int Rep 2018; 3:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellur SS, Troyanov S, Cook HT, et al. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant 2011; 26:2533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin DH, Lim BJ, Han IM, et al. Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy. Mod Pathol 2016; 29:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oortwijn BD, Rastaldi MP, Roos A, et al. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transplant 2007; 22:3191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts IS. Pathology of IgA nephropathy. Nat Rev Nephrol 2014; 10:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medjeral-Thomas NR, Troldborg A, Constantinou N, et al. Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition. Kidney Int Rep 2018; 3:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinosa M, Ortega R, Sánchez M, et al. Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2014; 9:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segarra A, Romero K, Agraz I, et al. Mesangial C4d Deposits in Early IgA Nephropathy. Clin J Am Soc Nephrol 2018; 13:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006; 17:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emancipator SN. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis 1994; 23:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang A, Kowalewska J, Smith KD, et al. A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clin Nephrol 2006; 66:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Karoui K, Hill GS, Karras A, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012; 23:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasri H, Mubarak M. Significance of vasculopathy in IgA nephropathy patients with regard to Oxford classification and immunostaining findings: a single center experience. J Renal Inj Prev 2013; 2:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sevillano ÁM, Cabrera J, Gutiérrez E, et al. Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. Nefrologia 2015; 35:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill GS, Nochy D, El Karoui K. Comments on the Oxford classification of IgA nephropathy. Kidney Int 2009; 76:1207; author reply 1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dysart NK Jr, Sisson S, Vernier RL. Immunoelectron microscopy of IgA nephropathy. Clin Immunol Immunopathol 1983; 29:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HS, Choi Y, Lee JS, et al. Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data. Kidney Int 1989; 35:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan X, Su Q, Wang H, et al. Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients. J Am Soc Nephrol 2023; 34:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthoux FC, Laurent B, Alamartine E, Diab N. New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or association. Nephrol Dial Transplant 1996; 11:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellur SS, Lepeytre F, Vorobyeva O, et al. Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 2017; 91:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int 2010; 77:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour SJ, Espino-Hernandez G, Reich HN, et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 2016; 89:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lv J, Shi S, Xu D, et al. Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2013; 62:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M, Verhave JC, Liu ZH, et al. A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. J Am Soc Nephrol 2017; 28:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trimarchi H, Barratt J, Cattran DC, et al. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int 2017; 91:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour SJ, Coppo R, Zhang H, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med 2019; 179:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki K, Honda K, Tanabe K, et al. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 2003; 63:2286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaber LW, Khan FN, Graviss EA, et al. Prevalence, Characteristics, and Outcomes of Incidental IgA Glomerular Deposits in Donor Kidneys. Kidney Int Rep 2020; 5:1914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanfilippo F, Croker BP, Bollinger RR. Fate of four cadaveric donor renal allografts with mesangial IgA deposits. Transplantation 1982; 33:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chacko B, John GT, Neelakantan N, et al. Presentation, prognosis and outcome of IgA nephropathy in Indian adults. Nephrology (Carlton) 2005; 10:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour SJ, Cattran DC, Kim SJ, et al. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int 2013; 84:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander S, Varughese S, Franklin R, et al. Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort. Kidney Int Rep 2021; 6:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Topham PS, Harper SJ, Furness PN, et al. Glomerular disease as a cause of isolated microscopic haematuria. Q J Med 1994; 87:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollock C, Liu PL, Györy AZ, et al. Dysmorphism of urinary red blood cells--value in diagnosis. Kidney Int 1989; 36:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutiérrez E, González E, Hernández E, et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol 2007; 2:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yata N, Nakanishi K, Shima Y, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 2008; 23:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbour SJ, Coppo R, Er L, et al. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int 2021; 99:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int 2018; 94:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pouria S, Feehally J. Glomerular IgA deposition in liver disease. Nephrol Dial Transplant 1999; 14:2279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire BM, Julian BA, Bynon JS Jr, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang NS, Wu ZL, Zhang YE, et al. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol 2003; 9:2004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noble-Jamieson G, Thiru S, Johnston P, et al. Glomerulonephritis with end-stage liver disease in childhood. Lancet 1992; 339:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amore A, Coppo R, Roccatello D, et al. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab Invest 1994; 70:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Wiel A, Valentijn RM, Schuurman HJ, et al. Circulating IgA immune complexes and skin IgA deposits in liver disease. Relation to liver histopathology. Dig Dis Sci 1988; 33:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welander A, Sundelin B, Fored M, Ludvigsson JF. Increased risk of IgA nephropathy among individuals with celiac disease. J Clin Gastroenterol 2013; 47:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornasieri A, Sinico RA, Maldifassi P, et al. IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger's disease). Br Med J (Clin Res Ed) 1987; 295:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppo R, Amore A, Roccatello D. Dietary antigens and primary immunoglobulin A nephropathy. J Am Soc Nephrol 1992; 2:S173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung CK, Barratt J. Gluten and IgA nephropathy: you are what you eat? Kidney Int 2015; 88:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beaufils H, Jouanneau C, Katlama C, et al. HIV-associated IgA nephropathy--a post-mortem study. Nephrol Dial Transplant 1995; 10:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz A, Bargman JM, Miller DC, et al. IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy? Clin Nephrol 1992; 38:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vignon M, Cohen C, Faguer S, et al. The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits. Kidney Int 2017; 91:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mustonen J, Pasternack A, Rantala I. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 1983; 20:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14:361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westhoff TH, Waldherr R, Loddenkemper C, et al. Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease? Clin Nephrol 2006; 65:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbiano di Belgiojoso G, Mazzucco G, Casanova S, et al. Steroid-sensitive nephrotic syndrome with mesangial IgA deposits: a separate entity? Observation of two cases. Am J Nephrol 1986; 6:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shima Y, Nakanishi K, Sato M, et al. IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatr Nephrol 2017; 32:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrassy K, Waldherr R, Erb A, Ritz E. De novo glomerulonephritis in patients during remission from Wegener's granulomatosis. Clin Nephrol 1992; 38:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergmann J, Buchheidt D, Waldherr R, et al. IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review. Am J Kidney Dis 2005; 45:e16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mak SK, Wong PN, Lo KY, Wong AK. Successful treatment of IgA nephropathy in association with low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type. Am J Kidney Dis 1998; 31:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson FP, Nasr SH, Markowitz GS, et al. A destructive nasal lesion and glomerulonephritis. Kidney Int 2006; 69:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernández JI, Gómez-Román J, Rodrigo E, et al. Bronchiolitis obliterans and IgA nephropathy. A new cause of pulmonary-renal syndrome. Am J Respir Crit Care Med 1997; 156:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hubert D, Beaufils M, Meyrier A. [Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases]. Presse Med 1984; 13:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch DJ, Jindal KK, Trillo A, Cohen AD. Acute renal failure in Crohn's disease due to IgA nephropathy. Am J Kidney Dis 1992; 20:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takemura T, Okada M, Yagi K, et al. An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications. Pediatr Nephrol 2002; 17:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int J Colorectal Dis 2005; 20:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Champtiaux N, Lioté F, El Karoui K, et al. Spondyloarthritis-Associated IgA Nephropathy. Kidney Int Rep 2020; 5:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joher N, Gosset C, Guerrot D, et al. Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrol Dial Transplant 2022; 37:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study. J Am Soc Nephrol 2021; 32:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamano C, Shimizu A, Joh K, et al. A cross-sectional study in patients with IgA nephropathy of correlations between clinical data and pathological findings at the time of renal biopsy: a Japanese prospective cohort study. Clin Exp Nephrol 2021; 25:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caster DJ, Abner CW, Walker PD, et al. Clinicopathological Characteristics of Adult IgA Nephropathy in the United States. Kidney Int Rep 2023; 8:1792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007; 71:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serino G, Pesce F, Sallustio F, et al. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney Int 2016; 89:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selvaskandan H, Shi S, Twaij S, et al. Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management. Front Immunol 2020; 11:572754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004; 66:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SY, Bu R, Zhang Q, et al. Clinical, Pathological, and Prognostic Characteristics of Glomerulonephritis Related to Staphylococcal Infection. Medicine (Baltimore) 2016; 95:e3386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr SH, D'Agati VD. IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease. Nephron Clin Pract 2011; 119:c18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maixnerová D, Tesař V, Ryšavá R, et al. The coincidence of IgA nephropathy and Fabry disease. BMC Nephrol 2013; 14:6.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3112 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23782179" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723227" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327382" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1680208" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : IgA nephropathy in blacks: studies of IgA2 allotypes and clinical course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29106637" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12213946" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30977248" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Is immunoglobulin A nephropathy different in different ethnic populations?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30450464" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21273233" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27102346" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17545679" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Demonstration of secretory IgA in kidneys of patients with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24861083" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pathology of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29725647" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24578331" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Association of C4d deposition with clinical outcomes in IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29146701" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mesangial C4d Deposits in Early IgA Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687629" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8128950" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : IgA nephropathy: morphologic expression and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9186068" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17176910" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22052055" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25340125" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Significance of vasculopathy in IgA nephropathy patients with regard to Oxford classification and immunostaining findings: a single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25611832" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910951" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comments on the Oxford classification of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6354536" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Immunoelectron microscopy of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2651762" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Ultrastructural changes in IgA nephropathy in relation to histologic and clinical data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36130833" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8671835" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27914703" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19571790" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19571791" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20200498" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26759049" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The MEST score provides earlier risk prediction in lgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23820066" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27612994" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28341274" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30980653" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753320" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Incidence of latent mesangial IgA deposition in renal allograft donors in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2516884" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Frequency of mesangial IgA deposits in a non-selected autopsy series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33163712" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prevalence, Characteristics, and Outcomes of Incidental IgA Glomerular Deposits in Donor Kidneys.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7041362" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fate of four cadaveric donor renal allografts with mesangial IgA deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16221102" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Presentation, prognosis and outcome of IgA nephropathy in Indian adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23739233" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33615067" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15524056" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8041865" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Glomerular disease as a cause of isolated microscopic haematuria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2689749" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dysmorphism of urinary red blood cells--value in diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699387" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18224344" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Improved renal survival in Japanese children with IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33220356" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Updating the International IgA Nephropathy Prediction Tool for use in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29804660" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Secondary IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3548338" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10528642" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Glomerular IgA deposition in liver disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16702589" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970894" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Role of hepatitis B virus infection in pathogenesis of IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347585" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Glomerulonephritis with end-stage liver disease in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8302021" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3371140" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Circulating IgA immune complexes and skin IgA deposits in liver disease. Relation to liver histopathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23442839" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Increased risk of IgA nephropathy among individuals with celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3113643" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : IgA-antigliadin antibodies in IgA mesangial nephropathy (Berger's disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1600133" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Dietary antigens and primary immunoglobulin A nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26230197" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Gluten and IgA nephropathy: you are what you eat?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7724026" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : HIV-associated IgA nephropathy--a post-mortem study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1516281" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : IgA nephritis in HIV-positive patients: a new HIV-associated nephropathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1495523" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069266" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The clinicopathologic characteristics of kidney diseases related to monotypic IgA deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6641024" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2816928" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16550751" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518456" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Steroid-sensitive nephrotic syndrome with mesangial IgA deposits: a separate entity? Observation of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27714465" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : IgA nephropathy with presentation of nephrotic syndrome at onset in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1468158" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15156525" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15696435" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : IgA nephropathy and hodgkin's disease: a rare coincidence. Case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531192" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Successful treatment of IgA nephropathy in association with low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16508654" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A destructive nasal lesion and glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9279256" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Bronchiolitis obliterans and IgA nephropathy. A new cause of pulmonary-renal syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6232533" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : [Immunoglobulin A glomerular nephropathy associated with inflammatory colitis. Apropos of 2 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1496975" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Acute renal failure in Crohn's disease due to IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12376818" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : An adolescent with IgA nephropathy and Crohn disease: pathogenetic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15668785" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : IgA nephropathy in association with Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32518863" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Spondyloarthritis-Associated IgA Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33416845" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33177116" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33595730" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : A cross-sectional study in patients with IgA nephropathy of correlations between clinical data and pathological findings at the time of renal biopsy: a Japanese prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37705898" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Clinicopathological Characteristics of Adult IgA Nephropathy in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19478457" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17342176" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26581012" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33123151" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327380" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15327381" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Outcome study of renal biopsy patients in Okinawa, Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27082609" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Clinical, Pathological, and Prognostic Characteristics of Glomerulonephritis Related to Staphylococcal Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21659781" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : IgA-dominant postinfectious glomerulonephritis: a new twist on an old disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23305247" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The coincidence of IgA nephropathy and Fabry disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
